Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

3
401
0
25

Year Published

2017
2017
2022
2022

Publication Types

Select...
10

Relationship

2
8

Authors

Journals

citations
Cited by 387 publications
(429 citation statements)
references
References 249 publications
3
401
0
25
Order By: Relevance
“…Many studies on the pharmacokinetics, pharmacodynamics, clinical efficacy and cellular mechanisms of metformin have informed a favourable benefit:risk ratio that, alongside costeffectiveness, has elevated this agent to the preferred first-line glucose-lowering pharmacological therapy for type 2 diabetes in major national and international treatment guidelines and algorithms (for examples, see [75][76][77][78]). Metformin has become the most prescribed glucose-lowering therapy worldwide and it is now included in the World Health Organization's (WHO's) essential medicines list [79].…”
Section: First-line Pharmacological Choicementioning
confidence: 99%
“…Many studies on the pharmacokinetics, pharmacodynamics, clinical efficacy and cellular mechanisms of metformin have informed a favourable benefit:risk ratio that, alongside costeffectiveness, has elevated this agent to the preferred first-line glucose-lowering pharmacological therapy for type 2 diabetes in major national and international treatment guidelines and algorithms (for examples, see [75][76][77][78]). Metformin has become the most prescribed glucose-lowering therapy worldwide and it is now included in the World Health Organization's (WHO's) essential medicines list [79].…”
Section: First-line Pharmacological Choicementioning
confidence: 99%
“…Согласно первой из них указанные препараты выступают лишь в роли триггеров (запускающих факторов) по отношению к СД. В то же время глю-кокортикоиды, являющиеся прямыми контринсу-лярными гормонами, могут выступать в качестве причины развития нарушений углеводного обмена [45].…”
Section: раздел 7 сахарный диабет и сердечно-сосудистая коморбидностьunclassified
“…Statin therapy is recommended as the first‐line lipid‐lowering drug therapy for the management of dyslipidemia in individuals with diabetes mellitus (unless contraindicated) in current major US guidelines and recommendations (summarized in Table S1). 1, 2, 4, 5 However, some patients with high cardiovascular risk either do not achieve adequate LDL‐C reductions on statins, or are intolerant to statins and therefore receive suboptimal statin doses or discontinue statin therapy, and thus remain at increased risk of cardiovascular events. For such patients, additional and/or alternative nonstatin lipid‐lowering treatment options should be considered 4, 6, 7, 8, 9, 10, 11, 12…”
mentioning
confidence: 99%